{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "C",
          "alt": "R",
          "position": "418"
        },
        "variant_string_id": "PARK2 C418R"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations of the ubiquitin ligase parkin account for most autosomal recessive forms of juvenile Parkinson's disease (AR-JP). Parkin has been characterized as a ubiquitin ligase that acts as a negative modulator of apoptosis, both in vitro and in vivo. Enzymatic activity of parkin is abolished by several mutations associated with AR-JP.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism of AR-JP as related to parkin mutations leading to loss of ubiquitin ligase activity and impaired modulation of apoptosis, which contributes to neuronal loss in Parkinson's disease."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses assays such as caspase-3 activity measurements, p53 expression and promoter transactivation assays, and chromatin immunoprecipitation (ChIP) to assess the transcriptional repressor activity of parkin on p53, independent of its ligase activity.",
          "judgment": "Yes",
          "reasoning": "The general classes of assays (e.g., caspase-3 activity for apoptosis, promoter transactivation for transcriptional regulation) are relevant to the disease mechanism of AR-JP, as they model the loss of protective function and transcriptional control linked to parkin mutations.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Wild-type parkin and empty vector controls were used in experiments (e.g., Fig. 3a-c). Caspase-3 activity and p53 expression assays were performed with multiple replicates (n=3-6 independent experiments in triplicate, as per Fig. 3 legends).",
          "judgment": "Yes",
          "reasoning": "Both normal (wild-type parkin, empty vector) and abnormal (mutant parkin) controls are included. The paper explicitly states multiple replicates for experiments, satisfying the criteria for basic controls and replicates.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "The study includes multiple parkin mutations (C418R, C441R, K161N, R256C) known to be associated with AR-JP as pathogenic controls, compared against wild-type parkin (Fig. 3a-c).",
          "judgment": "Yes",
          "reasoning": "Known pathogenic variants (including C418R) are used as controls in the assays, meeting the criteria for variant controls.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "Statistical analysis was performed with PRISM software using t-test or Newmann-Keuls multiple comparison tests (Methods). Specific p-values are reported for differences in caspase-3 activity and p53 expression (e.g., P<0.05, Fig. 3a-c).",
          "judgment": "No",
          "reasoning": "While statistical tests and p-values are provided, there is no direct calculation or estimation of OddsPath for pathogenicity likelihood from the functional data for this variant.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study includes at least 4 pathogenic variant controls (C418R, C441R, K161N, R256C) across the assays related to p53 regulation and caspase-3 activity (Fig. 3a-f).",
          "judgment": "No (less than 11 controls)",
          "reasoning": "The total number of benign and pathogenic variant controls used in the study is less than 11, which limits the strength of evidence to supporting level.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for PARK2 C418R supports pathogenicity at a supporting level (PS3_supporting) due to the use of relevant assays demonstrating loss of p53 transcriptional repression and failure to reduce caspase-3 activity, with adequate controls and replicates but insufficient variant controls (less than 11) and lack of OddsPath calculation."
    },
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "C",
          "alt": "R",
          "position": "441"
        },
        "variant_string_id": "PARK2 C441R"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations of the ubiquitin ligase parkin account for most autosomal recessive forms of juvenile Parkinson's disease (AR-JP). Parkin has been characterized as a ubiquitin ligase that acts as a negative modulator of apoptosis, both in vitro and in vivo. Enzymatic activity of parkin is abolished by several mutations associated with AR-JP.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism of AR-JP as related to parkin mutations leading to loss of ubiquitin ligase activity and impaired modulation of apoptosis, which contributes to neuronal loss in Parkinson's disease."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses assays such as caspase-3 activity measurements, p53 expression and promoter transactivation assays, and chromatin immunoprecipitation (ChIP) to assess the transcriptional repressor activity of parkin on p53, independent of its ligase activity.",
          "judgment": "Yes",
          "reasoning": "The general classes of assays (e.g., caspase-3 activity for apoptosis, promoter transactivation for transcriptional regulation) are relevant to the disease mechanism of AR-JP, as they model the loss of protective function and transcriptional control linked to parkin mutations.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Wild-type parkin and empty vector controls were used in experiments (e.g., Fig. 3a-c). Caspase-3 activity and p53 expression assays were performed with multiple replicates (n=3-6 independent experiments in triplicate, as per Fig. 3 legends).",
          "judgment": "Yes",
          "reasoning": "Both normal (wild-type parkin, empty vector) and abnormal (mutant parkin) controls are included. The paper explicitly states multiple replicates for experiments, satisfying the criteria for basic controls and replicates.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "The study includes multiple parkin mutations (C418R, C441R, K161N, R256C) known to be associated with AR-JP as pathogenic controls, compared against wild-type parkin (Fig. 3a-c).",
          "judgment": "Yes",
          "reasoning": "Known pathogenic variants (including C441R) are used as controls in the assays, meeting the criteria for variant controls.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "Statistical analysis was performed with PRISM software using t-test or Newmann-Keuls multiple comparison tests (Methods). Specific p-values are reported for differences in caspase-3 activity and p53 expression (e.g., P<0.05, Fig. 3a-c).",
          "judgment": "No",
          "reasoning": "While statistical tests and p-values are provided, there is no direct calculation or estimation of OddsPath for pathogenicity likelihood from the functional data for this variant.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study includes at least 4 pathogenic variant controls (C418R, C441R, K161N, R256C) across the assays related to p53 regulation and caspase-3 activity (Fig. 3a-f).",
          "judgment": "No (less than 11 controls)",
          "reasoning": "The total number of benign and pathogenic variant controls used in the study is less than 11, which limits the strength of evidence to supporting level.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for PARK2 C441R supports pathogenicity at a supporting level (PS3_supporting) due to the use of relevant assays demonstrating loss of p53 transcriptional repression and failure to reduce caspase-3 activity, with adequate controls and replicates but insufficient variant controls (less than 11) and lack of OddsPath calculation."
    },
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "K",
          "alt": "N",
          "position": "161"
        },
        "variant_string_id": "PARK2 K161N"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations of the ubiquitin ligase parkin account for most autosomal recessive forms of juvenile Parkinson's disease (AR-JP). Parkin has been characterized as a ubiquitin ligase that acts as a negative modulator of apoptosis, both in vitro and in vivo. Enzymatic activity of parkin is abolished by several mutations associated with AR-JP.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism of AR-JP as related to parkin mutations leading to loss of ubiquitin ligase activity and impaired modulation of apoptosis, which contributes to neuronal loss in Parkinson's disease."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses assays such as caspase-3 activity measurements, p53 expression and promoter transactivation assays, and chromatin immunoprecipitation (ChIP) to assess the transcriptional repressor activity of parkin on p53, independent of its ligase activity.",
          "judgment": "Yes",
          "reasoning": "The general classes of assays (e.g., caspase-3 activity for apoptosis, promoter transactivation for transcriptional regulation) are relevant to the disease mechanism of AR-JP, as they model the loss of protective function and transcriptional control linked to parkin mutations.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Wild-type parkin and empty vector controls were used in experiments (e.g., Fig. 3a-c). Caspase-3 activity and p53 expression assays were performed with multiple replicates (n=3-6 independent experiments in triplicate, as per Fig. 3 legends).",
          "judgment": "Yes",
          "reasoning": "Both normal (wild-type parkin, empty vector) and abnormal (mutant parkin) controls are included. The paper explicitly states multiple replicates for experiments, satisfying the criteria for basic controls and replicates.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "The study includes multiple parkin mutations (C418R, C441R, K161N, R256C) known to be associated with AR-JP as pathogenic controls, compared against wild-type parkin (Fig. 3a-c).",
          "judgment": "Yes",
          "reasoning": "Known pathogenic variants (including K161N) are used as controls in the assays, meeting the criteria for variant controls.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "Statistical analysis was performed with PRISM software using t-test or Newmann-Keuls multiple comparison tests (Methods). Specific p-values are reported for differences in caspase-3 activity and p53 expression (e.g., P<0.05, Fig. 3a-c).",
          "judgment": "No",
          "reasoning": "While statistical tests and p-values are provided, there is no direct calculation or estimation of OddsPath for pathogenicity likelihood from the functional data for this variant.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study includes at least 4 pathogenic variant controls (C418R, C441R, K161N, R256C) across the assays related to p53 regulation and caspase-3 activity (Fig. 3a-f).",
          "judgment": "No (less than 11 controls)",
          "reasoning": "The total number of benign and pathogenic variant controls used in the study is less than 11, which limits the strength of evidence to supporting level.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for PARK2 K161N supports pathogenicity at a supporting level (PS3_supporting) due to the use of relevant assays demonstrating loss of p53 transcriptional repression and failure to reduce caspase-3 activity, with adequate controls and replicates but insufficient variant controls (less than 11) and lack of OddsPath calculation."
    },
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "C",
          "position": "256"
        },
        "variant_string_id": "PARK2 R256C"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations of the ubiquitin ligase parkin account for most autosomal recessive forms of juvenile Parkinson's disease (AR-JP). Parkin has been characterized as a ubiquitin ligase that acts as a negative modulator of apoptosis, both in vitro and in vivo. Enzymatic activity of parkin is abolished by several mutations associated with AR-JP.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism of AR-JP as related to parkin mutations leading to loss of ubiquitin ligase activity and impaired modulation of apoptosis, which contributes to neuronal loss in Parkinson's disease."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses assays such as caspase-3 activity measurements, p53 expression and promoter transactivation assays, and chromatin immunoprecipitation (ChIP) to assess the transcriptional repressor activity of parkin on p53, independent of its ligase activity.",
          "judgment": "Yes",
          "reasoning": "The general classes of assays (e.g., caspase-3 activity for apoptosis, promoter transactivation for transcriptional regulation) are relevant to the disease mechanism of AR-JP, as they model the loss of protective function and transcriptional control linked to parkin mutations.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Wild-type parkin and empty vector controls were used in experiments (e.g., Fig. 3a-c). Caspase-3 activity and p53 expression assays were performed with multiple replicates (n=3-6 independent experiments in triplicate, as per Fig. 3 legends).",
          "judgment": "Yes",
          "reasoning": "Both normal (wild-type parkin, empty vector) and abnormal (mutant parkin) controls are included. The paper explicitly states multiple replicates for experiments, satisfying the criteria for basic controls and replicates.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "The study includes multiple parkin mutations (C418R, C441R, K161N, R256C) known to be associated with AR-JP as pathogenic controls, compared against wild-type parkin (Fig. 3a-c).",
          "judgment": "Yes",
          "reasoning": "Known pathogenic variants (including R256C) are used as controls in the assays, meeting the criteria for variant controls.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "Statistical analysis was performed with PRISM software using t-test or Newmann-Keuls multiple comparison tests (Methods). Specific p-values are reported for differences in caspase-3 activity and p53 expression (e.g., P<0.05, Fig. 3a-c).",
          "judgment": "No",
          "reasoning": "While statistical tests and p-values are provided, there is no direct calculation or estimation of OddsPath for pathogenicity likelihood from the functional data for this variant.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study includes at least 4 pathogenic variant controls (C418R, C441R, K161N, R256C) across the assays related to p53 regulation and caspase-3 activity (Fig. 3a-f).",
          "judgment": "No (less than 11 controls)",
          "reasoning": "The total number of benign and pathogenic variant controls used in the study is less than 11, which limits the strength of evidence to supporting level.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for PARK2 R256C supports pathogenicity at a supporting level (PS3_supporting) due to the use of relevant assays demonstrating loss of p53 transcriptional repression and failure to reduce caspase-3 activity, with adequate controls and replicates but insufficient variant controls (less than 11) and lack of OddsPath calculation."
    }
  ]
}